An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females.
DelveInsight's newsletter series brings to light an overview of Pompe disease, underlying cause, etiology, and symptoms.
The newsletter provides a brief scenario of the prevalence and incidence of the disease, present treatment approaches and the therapies and drugs in the pipeline for the disease. The newsletter also covers the present market scenario and the companies that are working to shift the Pompe disease market in the coming decade with key collaborations, and partnerships along with top conferences that are going to take place in the following year.
Download our newsletter by filling up the form and gain access to deep and rich insights into Pompe disease market.
Want analytical information related to Rare Diseases directly delivered to your inbox? Join DelveInsight's emailer list and gain a competitive edge.
Stay tuned for more.
Know more about What's covered:
- Indication overview
- Treatment approaches
- Pipeline drugs
- Key Companies
- Support from International organizations